Pomalidomide and Pacritinib: Interaction Details

Brand names
Pomalidomide
Pomalyst
Pacritinib
Vonjo
Dr. Brian Staiger, PharmD, BCPS

Medically reviewed by ⁠

Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
Share

Share this interaction

What Happens When You Take Pomalidomide With Pacritinib

What can happen when they are taken together (rated Major)

Increased with NTI exposure and an increased risk of CYP1A2 substrate with NTI-related adverse reactions

Interaction Deep Dive

A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →

When pacritinib, a CYP1A2 , is given together with a CYP1A2 substrate that has a (NTI), exposure to that substrate may rise, and this in turn may raise the likelihood of adverse reactions associated with the substrate. More frequent monitoring for adverse reactions related to the CYP1A2 substrate is recommended.1

The Pomalidomide and Pacritinib Interaction, Explained

Pacritinib can raise the level of pomalidomide in your body. Pacritinib slows down , one of the enzymes that helps clear pomalidomide. When that happens, more pomalidomide can stay in your system, which may increase its side effects. These can include low blood counts, tiredness, infections, blood clots, and nerve problems.

Pomalidomide is a drug where small changes in the level can matter. Please do not stop or change either medicine on your own. Your care team can adjust and individualize your dose and may check on you more often to manage this safely.

Mechanism: Pacritinib inhibits , a primary pathway for pomalidomide ( is a minor contributor). Expect increased pomalidomide exposure (/) and a higher risk of dose-related adverse reactions. The database classifies pomalidomide as a CYP1A2 with a .

  • Direction: increased pomalidomide exposure.
  • Severity: major. Evidence: probable. Onset: unspecified.
  • Magnitude: not quantified in the data on file.
  • Management: monitor more frequently for pomalidomide-related adverse reactions (e.g., , thromboembolism, neuropathy, infection). Individualize the dose as clinically needed.

See the 1 reference behind this explanation ↓

From the HelloPharmacist Pharmacy Team

AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .

How we build these pages · How we use AI · Our editorial policy

Why Pomalidomide and Pacritinib Interact

The likely mechanism

of -substrate by pacritinib

How Drug Interactions Work Six short figures, about a minute: how one drug can raise or lower another’s level, or add to or cancel its effect. See how it works 

How to Manage the Pomalidomide and Pacritinib Interaction

Your care team can manage this combination, usually with closer monitoring.

  • Your team may monitor you more closely for pomalidomide side effects.
  • The pomalidomide dose may need to be adjusted and individualized by your care team.
  • Keep taking both medicines exactly as prescribed unless told otherwise.
  • Tell your pharmacist or doctor promptly about unusual bruising or bleeding, fever or infection signs, swelling or pain in a leg, numbness or tingling, or new tiredness.

Management is individual — confirm any change with your pharmacist or prescriber.

Questions for Your Pharmacist

  • Does my dose of Pomalidomide or Pacritinib need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there another option that avoids this interaction?

Literature Reports

1 report from the published literature. Each one is headed by the title of the published study it comes from.

What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.

  1. Report 1 · Study title

    Prescribing information: VONJO oral capsules, pacritinib oral capsules

    A drug interaction study found that when pacritinib 200 mg twice daily was coadministered with caffeine 100 mg (a ), caffeine increased by 0.99-fold and caffeine increased by 1.22-fold, respectively.1

Pomalidomide and Pacritinib: Common Questions

How serious is the Pomalidomide and Pacritinib interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How is the Pomalidomide and Pacritinib interaction managed?

Your care team can manage this combination, usually with closer monitoring. Your team may monitor you more closely for pomalidomide side effects. The pomalidomide dose may need to be adjusted and individualized by your care team. Keep taking both medicines exactly as prescribed unless told otherwise. Tell your pharmacist or doctor promptly about unusual bruising or bleeding, fever or infection sig… Management is individual — always follow your own care team's guidance.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "probable". Good supporting evidence, though not definitively proven.

Ask About the Pomalidomide and Pacritinib Interaction

Ask in your own words about taking Pomalidomide and Pacritinib together. The answer comes from this page’s interaction record and both drugs’ own information.

This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.

Try:

AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.

References (1)

  1. Product Information: VONJO(R) oral capsules, pacritinib oral capsules. CTI BioPharma Corp (per FDA), Seattle, WA, 2024. DailyMed
Was this write-up helpful?

Other Serious Interactions of Pomalidomide and Pacritinib

Also serious with Pomalidomide

Also serious with Pacritinib

These Medications Also Interact With Supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

With Pomalidomide

With Pacritinib

Check everything you take with our drug–supplement interaction checker.

Still Have Questions About This Combination?

Every question gets a real answer from a licensed pharmacist — free, as soon as they can.

About This Library

Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →

What Each Rating Means

Severity Levels

  • Contraindicated These should generally not be used together.
  • Major Potentially serious — often needs a change or close monitoring. This interaction.
  • Moderate Can be significant — usually manageable with monitoring.
  • Minor Usually limited clinical impact.

Evidence Grades

  • EstablishedWell documented — supported by controlled studies or strong clinical data.
  • ProbableGood supporting evidence, though not definitively proven. This interaction.
  • SuspectedSome evidence suggests this interaction, but it is not well established.
  • PossibleLimited or conflicting evidence; the interaction may occur.
  • TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.

How Soon It Shows

  • RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
  • DelayedEffects tend to build up gradually over days to weeks.
  • UnspecifiedThe timing of this interaction is not well characterized. This interaction.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Back to the answer
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.